Emmaus Life Sciences (Formerly Known As Emmaus Medical, Inc.)

103 articles with Emmaus Life Sciences (Formerly Known As Emmaus Medical, Inc.)

• Emmaus Life Sciences Release: Yutaka Niihara, MD, MPH, CEO Of Pharma, Appointed Executive Chairman Of Generex Biotechnology Corporation

  1/25/2017

• Generex Biotechnology Corporation Release: Company Announces Deal To Acquire Controlling Equity Interest In Emmaus Life Sciences

  1/23/2017

• Emmaus Life Sciences Receives Japanese Patent For Use Of L-Glutamine In Treatment Of Diverticulosis

  12/13/2016

• Emmaus Life Sciences Receives Notice Of FDA PDUFA Date For Investigational L-Glutamine Treatment For Sickle Cell Disease

  11/29/2016

• Emmaus Life Sciences' New Drug Application For Sickle Cell Disease Accepted For Review By FDA

  11/9/2016

• LA's Emmaus Life Sciences Raises $6 Million From Korean Investors

  10/4/2016

• Emmaus Life Sciences Completes $20 Million Private Placement From Two Korean-based Public Companies

  10/3/2016

• Emmaus Life Sciences Submits New Drug Application For Sickle Cell Disease Treatment

  9/8/2016

• Emmaus Life Sciences to Seek Marketing Approval for First New Sickle Cell Disease Treatment in Nearly 20 Years; Expects to Submit New Drug Application to FDA in September

  8/22/2016

• Emmaus Life Sciences Announces Management Promotions

  2/3/2016

• Emmaus Life Sciences Announces New Board Members

  2/1/2016

• SoCal's Emmaus Life Sciences Reappoints Co-founder and Chairman as CEO

  1/26/2016

• Emmaus Life Sciences Secures Funding To Advance Sickle Cell Disease Treatment

  1/26/2016

• Emmaus Medical, Inc. Announces Completion Of All Patient Visits For Its Phase 3 Clinical Trial For Treatment Of Sickle Cell Disease

  1/7/2014

• Former FDA Official Tim Cote JoinsEmmaus Medical, Inc. as Regulatory Advisor

  5/9/2013

• Emmaus Medical, Inc. to Present at 6th Annual OneMedForum

  12/20/2012

• Emmaus Medical, Inc. Announces Completion of Enrollment for Its Phase 3 Sickle Cell Disease Trial

  12/3/2012

• Emmaus Medical, Inc. CEO Yutaka Niihara, M.D., Issues Statement in Connection With Status of Company's Phase III FDA Sickle Cell Treatment Trials

  11/19/2012

• Emmaus Medical, Inc. Marks Progression of Phase 3 Sickle Cell Disease Clinical Trial During Sickle Cell Awareness Month

  9/13/2012

• European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical, Inc.'s Sickle Cell Treatment

  7/17/2012